Verona Pharma 주식 가격. VRNA - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

다우존스 지수

같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Verona Pharma Plc (VRNA) 시세

Verona Pharma Plc (VRNA)

38.85

0.76

(2.00%)

마감 21 11월 6:00AM

39.02

0.17

( 0.44% )

시간외 단일가: 11:24PM

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

가격

39.02

매수가

39.02

매도가

40.30

거래량

8,318

0.00 일간 변동폭 0.00

0.00 52주 범위 0.00

market_cap

전일 종가

38.85

개장가

-

최근 거래 시간

마지막 거래 시간

23:21:44

재정 규모

-

VWAP

-

평균 볼륨(3m)

-

발행 주식

81,831,170

배당수익률

-

주가수익률

0.00

주당순이익(EPS)

-

매출

-

순이익

-54.37M

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which ... Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. 더 보기

섹터

Pharmaceutical Preparations

산업

Pharmaceutical Preparations

웹사이트

www.veronapharma.com

본부

London, Gbr

설립됨

-

Verona Pharma Plc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker VRNA. The last closing price for Verona Pharma was US$38.85. Over the last year, Verona Pharma shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Verona Pharma currently has 81,831,170 shares in issue. The market capitalisation of Verona Pharma is US$3.18 billion.

Verona Pharma Announces December 2024 Investor Conference Participation

LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Verona Pharma to Present at Jefferies London Healthcare Conference

LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

가장 활성
% 상승자
% 패자

기호	가격	볼륨
AALAmerican Airlines Group Inc	US$ 14.46 (0.00%)	126.07k
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 67.36 (0.00%)	0
AADIAadi Bioscience Inc	US$ 2.22 (0.00%)	415
AACGATA Creativity Global	US$ 1.02 (0.00%)	185
AALAmerican Airlines Group Inc	US$ 14.46 (0.00%)	151.09k
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 67.36 (0.00%)	0
AADIAadi Bioscience Inc	US$ 2.22 (0.00%)	415
AACGATA Creativity Global	US$ 1.02 (0.00%)	185
CDTConduit Pharmaceuticals Inc	US$ 0.0923 (0.00%)	206.08M
AKTSAkoustis Technologies Inc	US$ 0.0871 (0.00%)	130.86M
PETWag Group Company	US$ 0.2101 (0.00%)	29.14M
WORXSCWorx Corporation	US$ 0.98 (0.00%)	27.51M
NVDANVIDIA Corporation	US$ 145.89 (0.00%)	26.4M

powerwalker

powerwalker 16 시간 전

Does anyone have thoughts on yesterday's presentation? I read the slides and come away with the impression that Verona can serve 50% of the market with the focus on 80% of the HCPs intent to Prescribe Ohtuvayre.

With $1.1 billion in sales for each !% or 86K patients, those are BIG numbers down the road as Mega and Hoskuld shared earlier this week.

MegaPirate61

MegaPirate61 2 일 전

Just search fintel Duquesne position of 680k shares you can validate this on multiple sites. Use ai in your searches lol

powerwalker

powerwalker 2 일 전

Mega, article is behind a pay-wall for CNBC, so can't see it.

I think he will buy more ... sooner, rather than later.

Roger1

Roger1 2 일 전

It is in process. Mixup at doctors office. Verona and Acaria have been very supportive and helpful. Should be straightened out today.

powerwalker

powerwalker 2 일 전

Roger, it appears that folks there liked what they heard as well as Druckenmiller's $20 million purchase would have encourage others to buy now. [I did not find anything, either. Possibly, later today it will be available.]

BTW, how is your situation? Have you received it?

Roger1

Roger1 2 일 전

I thought the presentation was to be webcast and found on the investor tab. I didn't find it this morning at 0630. Anyone else?

powerwalker

powerwalker 2 일 전

Verona Pharma Announces December 2024 Investor Conference Participation

https://www.veronapharma.com/news/verona-pharma-announces-december-2024-investor-conference-participation/

Not the PR I was expecting for this morning ... hoping for data being shown today at Jefferies conference.

powerwalker

powerwalker 3 일 전

Mega, great find. He is a top-notch investor.

MegaPirate61

MegaPirate61 3 일 전

This guy Druckenmiller bought $20 mil worth vrna last month. https://www.cnbc.com/2024/11/18/druckenmiller-bought-regional-banks-but-a-healthcare-pick-is-his-biggest-bet.html

It's listed in a fund he manages. Duquesne.

powerwalker

powerwalker 3 일 전

PR in morning before NYSE opens?

MegaPirate61

MegaPirate61 3 일 전

Especially if soc in asthma and label expansion seasonal allergies... then it's worth is really high for that spring pollen pop. If international then it will be a bicyclical which would smooth the revenue curve. Lots of if statements of course.

Hoskuld

Hoskuld 6 일 전

Right - if SOC then this blows up in a good way.

powerwalker

powerwalker 7 일 전

On November 19th, possibly updates on scripts//sales ...

Verona Pharma to Present at Jefferies London Healthcare Conference

https://finance.yahoo.com/news/verona-pharma-present-jefferies-london-070000088.html

powerwalker

powerwalker 1 주 전

Hoskuld, any thing new on the scripts? Tough day yesterday.

MegaPirate61

MegaPirate61 1 주 전

I'm seeing a lot of soc references in the commentary from the analysts and physicians networks. If that happens in asthma and copd it's 20 billion per month. Obviously that's a long shot but it's possible in 10 yrs. That's the scary thing.

Hoskuld

Hoskuld 1 주 전

LOL I like your sign off! I don't think most COPD patients will switch to ohtuvayre but will just add Oh (steroids are pretty cheap.) Add 250,000 bronchiectasis patients to probably 1.5m COPD patients and those add up to some immense numbers. Maybe I lack imagination, but I don't think $100b is in the cards - maybe $20b if every single thing goes well.

MegaPirate61

MegaPirate61 2 주 전

New valuation of vrna at 218 per share per takeover advocate specialist Caligan.

https://www.cnbc.com/2024/11/09/caligan-takes-a-stake-in-verona-pharma-sees-opportunity-to-generate-more-value.html

I personally feel this estimate is way low. If a big part 4 million copd patients on steroids are switched over to ohtuvayre as fda is pushing, plus other combos in a progressive disease scenario (meaning eventually all copd patients will need something else to supplement their therapy) you're looking at 3300 per 3 month supply or 13 billion per quarter. Double that for the 1 million fibrosis patients plus asthmatic patients once approved, and that's 100 bil per yr + without international or other label expansion. Fairly safe to say it's a 250 billion dollar asset in 10 yrs all imo.

I'd put fair value at 2000 per share minimum. But what do I know I'm just a pirate. Ohtuvayrrrg!

Hoskuld

Hoskuld 2 주 전

And scripts are trending up in a big way - recently they have been doubling every 4 weeks.

MegaPirate61

MegaPirate61 2 주 전

Insider purchases that appear to be about 200 grand worth, possible exercises of options but marked as acquired nov 6

powerwalker

powerwalker 2 주 전

Why the pop over the last 90 minutes or so?

Hoskuld

Hoskuld 2 주 전

Hi PW! Scripts will just tell us the trend - which is strong right now - but cannot give us the absolute #s...which are about 2.5x-3x the IMS script data. I think the company would consider a buyout at the right price - IMO $100 right now would be OK based on the trend and the upside is huge from there.

powerwalker

powerwalker 2 주 전

Thank you for your reply.

As to 1), will we learn of those higher revenues directly from Verona or indirectly via the weekly script info?

For 2), are the company's actions geared towards a take-out soon or later when more revenue sources are likely? or, will Glaxo and AZ jump the gun and go after Verona now that revenue is coming in strong for a sensational product?

Once again, thank you, Hoskuld.

Hoskuld

Hoskuld 2 주 전

I think there are 2 catalysts:

1. The continuous catalyst of higher and higher revenues and

2. Acquisition by Glaxo or AstraZeneca etc.

It will take a while for Bronchiectasis trial results but those will help, too.

powerwalker

powerwalker 2 주 전

Hoskuld, thanks for your post, to which I agree. What are the next catalysts for the stock ... or we wait until next year for Q4 and total 2024 numbers?

TYIA

Hoskuld

Hoskuld 2 주 전

Hi Powerwalker. These were great results. The actually scripts are much much higher than the IMS scripts indicate. This is trending to be a blockbuster by the end of next year. VRNA is going to be one of those big winners - and because it is now backed up by revenue, it is far less risky now from a PPS pov.

powerwalker

powerwalker 2 주 전

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

https://finance.yahoo.com/news/verona-pharma-reports-third-quarter-070000243.html

One has to like that October sales were HIGHER than Q3's.

powerwalker

powerwalker 3 주 전

Hoskuld, have you seen any numbers?

TYIA

MegaPirate61

MegaPirate61 3 주 전

All my best to you Roger. Noticed the earnings which is always on thursdays is now on Monday. Can't help but wonder if Ligand wants a bigger stake than just low single digit royalty on ohtuvayre. Though a takeout by azn is possible I think ligand all stock deal or 5 to 10% buy in is far more likely.

powerwalker

powerwalker 3 주 전

Roger, that will be great. God bless you and your family. Hopefully, you are among the new script numbers for next week.

Roger1

Roger1 3 주 전

Hopefully next week. Thanks for asking.

powerwalker

powerwalker 3 주 전

Roger, thank you for the article. How is your pursuit to utilize ensifentrine going?

Roger1

Roger1 3 주 전

https://share.newsbreak.com/9lxcziaz

Happy to see this.

powerwalker

powerwalker 3 주 전

Thank you, Hoskuld. Looking forward to next Monday, November 4th.

MegaPirate61

MegaPirate61 3 주 전

Did we know the next weekly oct 18 script info yet?

Hoskuld

Hoskuld 3 주 전

Sometimes it is difficult to say what option trades indicate - options are often part of hedging strategies. I am bullish on VRNA but these options sales/purchases could signify different expectations or similar expectations...who knows?

powerwalker

powerwalker 4 주 전

It looks as if someone (not me) is interested in the March 2025 $30 calls. There were 90 contracts traded yesterday and 40 today. Hope the buyer is right!

Hoskuld

Hoskuld 1 월 전

We should have 10/18 and 10/24 script data by then...

powerwalker

powerwalker 1 월 전

Thank you, Hoskuld.

Verona cc on 11/4 with Q3 stats ... hopefully, it is a good sign being first thing on a Monday morning. They are anxious to talk!

Hoskuld

Hoskuld 1 월 전

Yes - 324 week ending 10/11

powerwalker

powerwalker 1 월 전

Hoskuld, does that mean the scripts are over 300? Higher?

TYIA

Hoskuld

Hoskuld 1 월 전

Scripts are trending up strongly now - more than 3x 4 weeks ago.

Hoskuld

Hoskuld 1 월 전

IMO $70-$100 by the end of 2025.

powerwalker

powerwalker 1 월 전

All the best, Roger.

I sent message via its web site over the weekend asking about Marketing here in the States. I'll let you know when I hear back from them.

Roger1

Roger1 1 월 전

Still in process of getting it. Delay is on my end with my Dr. Should be resolved next month with new doc. I can tell you that Verona reached out to me almost immediately after my inquiry in August and have texted and emailed since. They have been very responsive. Very positive feelings about this company.

powerwalker

powerwalker 1 월 전

So, Roger, are you using Ohtuvayre? If so, is it meeting your expectations? TYIA

Roger1

Roger1 1 월 전

Acaria Health is one of the fulfillment pharmacies. They are handling me.

powerwalker

powerwalker 1 월 전

Roger, Hoskuld has access to such data but did not specify the numbers. See post #214.

Roger1

Roger1 1 월 전

Do. you have a link to your info by any chance? Release, conference, etc? TIA

powerwalker

powerwalker 1 월 전

Thank you, Hoskuld, for the information.

Do you have any numbers to share ... and get some people excited. TYIA

Hoskuld

Hoskuld 1 월 전

Prescription fulfillment is finally accelerating. Buckle up.

👍️ 1 👏 1

Agility Real Estate (GM)

Swiss Prime Rate

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관